Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.

Allergy News

12/20/2024
AllergyBreakingChinaDeals
Nicox Reports First Sale of Zerviate in China by Partner Ocumension
Nicox Reports First Sale of Zerviate in China by Partner Ocumension

France’s Nicox reported Dec. 4 that its partner Ocumension Therapeutics had made the first commercial sale of Zerviate (cetirizine ophthalmic solution) 0.24% in China. Zerviate is indicated for ocu...

11/27/2024
AllergyBreakingCataractDry EyePharma
Harrow Lowers Price of Drugs through GoodRx Partnership, Price Cuts
Harrow Lowers Price of Drugs through GoodRx Partnership, Price Cuts

Harrow, of Nashville, Tennessee reported Nov. 13 that it had entered into a partnership with GoodRx to provide patients for whom insurance is not a viable option a cash-pay alternative. Harrow prod...

11/14/2024
AllergyCataractClinical TrialCornealGlaucomaNewsletterPresbyopiaRetinaSurgical
Clinical Trial Updates for Ophthalmic Candidates, November 2024
Clinical Trial Updates for Ophthalmic Candidates, November 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

9/20/2024
AllergyBreakingChinaDealsRegulation
Nicox Reports that Ocumension Has Gained Approval for Zerviate in China
Nicox Reports that Ocumension Has Gained Approval for Zerviate in China

France’s Nicox announced Sept. 18 that partner Ocumension Therapeutics had received regulatory approval in China to commercialize Nicox’ Zerviate (cetirizine ophthalmic solution) 0.24% for ocular i...

7/26/2024
AllergyBreakingDry Eye
New OTC Eye Lubricants Available from AbbVie, Ocusoft
New OTC Eye Lubricants Available from AbbVie, Ocusoft

AbbVie has introduced two new preservative-free lubricant eye drop products—Refresh Tears PF and Refresh Relieva PF Xtra. AbbVie, of North Chicago, Illinois, said the new products feature a soft-sq...

3/21/2024
AllergyDiagnosticDry EyeEmergingGene TherapyGlaucomaNewsletterRetina
Emerging Companies Pursuing Ophthalmic Indications, March 2024
Emerging Companies Pursuing Ophthalmic Indications, March 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

2/23/2024
AllergyBreakingCataractChinaPharma
Regulators in Singapore Accept NDA from AffaMed for Dextenza
Regulators in Singapore Accept NDA from AffaMed for Dextenza

Shanghai-based AffaMed Therapeutics announced Feb. 19 that the Singapore Health Sciences Authority had accepted its new drug application (NDA) for Dextenza (0.4 mg dexamethasone intracanalicular in...

2/16/2024
AllergyBreakingDealsDry EyePharmaSurgical
Harrow Licenses Rights to Five Drugs to Apotex for Canada
Harrow Licenses Rights to Five Drugs to Apotex for Canada

Harrow reported Feb. 15 that it had licensed to Apotex exclusive marketing and distribution rights to Verkasia and over-the-counter Cationorm Plus in the Canadian market. In addition, Apotex will p...

1/5/2024
AllergyBreakingIndiaRegulation
US FDA Approves Generic Loteprednol Etabonate Drops from India’s Lupin for Seasonal Allergy
US FDA Approves Generic Loteprednol Etabonate Drops from India’s Lupin for Seasonal Allergy

Indian drugmaker Lupin announced Dec. 27 that the US FDA had approved its abbreviated new drug application for loteprednol etabonate ophthalmic suspension, 0.2%, a generic equivalent of Bausch + Lo...

Want to Read the Full Article?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more